MediWound (NASDAQ:MDWD) PT Set at $31.00 by HC Wainwright

MediWound (NASDAQ:MDWD - Get Free Report) received a $31.00 price target from equities researchers at HC Wainwright in a research report issued on Thursday, Marketbeat reports. The firm currently has a "buy" rating on the biopharmaceutical company's stock. HC Wainwright's price objective points to a potential upside of 45.34% from the stock's previous close.

Other analysts also recently issued research reports about the stock. Wall Street Zen raised shares of MediWound to a "sell" rating in a research report on Friday, March 21st. Craig Hallum started coverage on MediWound in a report on Friday, February 28th. They issued a "buy" rating and a $39.00 price target for the company. Finally, Alliance Global Partners assumed coverage on MediWound in a report on Friday, May 2nd. They issued a "buy" rating and a $25.00 price target for the company. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $31.25.

MediWound Stock Performance

MDWD traded up $0.96 on Thursday, reaching $21.33. 52,140 shares of the company's stock were exchanged, compared to its average volume of 91,324. The company's 50 day moving average is $17.50 and its 200-day moving average is $17.65. The company has a market cap of $230.53 million, a price-to-earnings ratio of -7.34 and a beta of 0.30. MediWound has a twelve month low of $12.78 and a twelve month high of $24.00.

MediWound (NASDAQ:MDWD - Get Free Report) last posted its earnings results on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $0.58. The firm had revenue of $3.96 million during the quarter, compared to the consensus estimate of $5.20 million. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same quarter in the prior year, the company earned ($1.05) EPS. Sell-side analysts forecast that MediWound will post -2.66 EPS for the current year.

Hedge Funds Weigh In On MediWound

Several institutional investors and hedge funds have recently made changes to their positions in MDWD. Yelin Lapidot Holdings Management Ltd. boosted its stake in shares of MediWound by 13.4% during the 4th quarter. Yelin Lapidot Holdings Management Ltd. now owns 851,361 shares of the biopharmaceutical company's stock valued at $15,154,000 after buying an additional 100,618 shares during the last quarter. Northern Trust Corp raised its position in shares of MediWound by 94.6% during the 4th quarter. Northern Trust Corp now owns 144,768 shares of the biopharmaceutical company's stock valued at $2,577,000 after acquiring an additional 70,367 shares in the last quarter. Essex Investment Management Co. LLC raised its position in shares of MediWound by 30.7% during the 4th quarter. Essex Investment Management Co. LLC now owns 148,949 shares of the biopharmaceutical company's stock valued at $2,651,000 after acquiring an additional 35,012 shares in the last quarter. MGO One Seven LLC acquired a new stake in shares of MediWound during the 4th quarter valued at approximately $216,000. Finally, Silverberg Bernstein Capital Management LLC raised its position in shares of MediWound by 13.1% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 103,944 shares of the biopharmaceutical company's stock valued at $1,613,000 after acquiring an additional 12,060 shares in the last quarter. 46.83% of the stock is currently owned by hedge funds and other institutional investors.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.